SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K was filed by BioSig Technologies, Inc. on January 12, 2024, reporting events occurring on the same date. The company is incorporated in Delaware and trades on the NASDAQ Capital Market under the symbol BSGM. The filing details a private placement of equity securities to raise capital.
Key Financial Metrics and Transaction Details
The filing discloses a specific capital raise transaction rather than periodic financial performance metrics such as revenue or operating margins.
- Gross Proceeds: $1,040,000.11
- Common Shares Sold: 2,607,170 shares
- Price Per Share: $0.3989
- Warrants Issued: 1,303,585 warrants (purchasable at a 1:2 ratio with shares)
- Warrant Exercise Price: $0.3364 per share
- Warrant Terms: Exercisable after six months; expire five and one-half years from issuance.
The filing text does not provide clear values for current revenue, profit, cash flow, total debt, or liquidity positions outside of the proceeds from this specific transaction.
Material Changes
The primary material change is the entry into a Securities Purchase Agreement with accredited and institutional investors. This transaction increases the company's share count and outstanding warrants. The securities were sold in reliance on exemptions from registration under Section 4(a)(2) and Regulation D (Rule 506) of the Securities Act of 1933.
Outlook, Risks, and Management Commentary
Management commentary is limited to the execution of the Purchase Agreement. The agreement includes standard representations, warranties, and covenants typical for such transactions. No specific forward-looking guidance, risk factors, or contingencies beyond the standard terms of the warrant exercise and expiration are detailed in this summary text.
Investor Verification Checklist
- Verify the dilution impact of the 2,607,170 new shares and 1,303,585 warrants on existing shareholders.
- Confirm the use of proceeds from the $1.04 million raise as disclosed in subsequent filings or press releases.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants or restrictions on the company's operations.
- Monitor the warrant exercise timeline, noting the six-month lock-up period before they become exercisable.